

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Starpharma Holdings Ltd
ABN 20 078 532 180

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jacinth K Fairley
Date of last notice	20 March 2008

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	31 March 2010
No. of securities held prior to change	53,750 Ordinary Shares (indirect) 650,000 Options (SPLAM – various exercise prices and expiry dates) (The last notice dated 20 March 2008 contained a typographical error - 50,750 instead of 53,750. The above totals are correct and consistent with the 2009 Annual Report.)
Class	1. Ordinary Shares 2. Rights
Number acquired	1. 1,428,571 Ordinary Shares 2. 750,000 Rights
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>No consideration - as set out in the Explanatory Memorandum that accompanied the Notice of Extraordinary General Meeting mailed to shareholders on 22 February 2010.</p>
<p>No. of securities held after change</p>	<p>1. 1,428,571 Ordinary Shares (direct) 2. 750,000 Rights 3. 53,750 (indirect) Dr Ian Fraser <Fraser Fairley Super A/C> 4. 650,000 Options (SPLAM)</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of securities following shareholder approval of CEO incentive plan.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	
<p>Nature of interest</p>	
<p>Name of registered holder (if issued securities)</p>	
<p>Date of change</p>	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	
<p>Interest acquired</p>	
<p>Interest disposed</p>	
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<p>Interest after change</p>	

+ See chapter 19 for defined terms.